Biohaven
BHVN
11.88
-0.20
-1.66%
Biohaven
US · BHVN
#2805 by market cap
Listed 2017
11.88
-0.20
-1.66%
Live - 5344 symbols - heartbeat 490s ago
· 2026-10-08 06:47
Pre-market
12.25
+3.11%
After-hours
11.88
0.00%
Overnight
11.88
0.00%
- Market cap
- 1.79B
- P/E (TTM)i
- -2.61
- P/Bi
- 146.67
- EPSi
- -6.86
- Div yieldi
- 0.00%
- 52W posi
- 40%
Reader sentiment
Are you bullish or bearish on BHVN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.7 percentage points.
Institutional ownership
- Held by institutions
- 94.74% +0.74pp
- Institutions
- 339 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund48.06%
Hedge Fund35.23%
Individual/Insider10.94%
Private Company3.91%
Public Company3.83%
VC/PE Fund2.00%
Insurance Company0.90%
Government Pension Fund0.47%
Family Office/Trust0.33%
Top holders as of 2026-06-30
BlackRock
8.75% · 13.21M sh
Montanova Capital, LLC
6.81% · 10.29M sh
Stifel Asset Management Corp.
6.58% · 9.94M sh
John Childs
6.54% · 9.88M sh
Janus Henderson Group plc
5.68% · 8.58M sh
Woodline Partners LP
5.07% · 7.66M sh
State Street Global Advisors
4.60% · 6.95M sh
Infinitum Asset Management, LLC
4.14% · 6.25M sh
D. E. Shaw & Co., L.P.
2.77% · 4.19M sh
AQR Capital Management
2.70% · 4.08M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 37 buys · 9 sells
| Name | Role | Stake |
|---|---|---|
| John Childs | Independent Director | 6.54% |
| Vladimir Coric | Chairperson & CEO | 2.55% |
| Gregory Bailey | Independent Director | 1.34% |
| Warren Volles | General Counsel & Chief Legal Officer | 0.16% |
| Matthew Buten | Chief Financial Officer | 0.13% |
| Kimberly Gentile | Senior Vice President of Clinical Operations | 0.07% |
| George Clark | Vice President | 0.06% |
| Bruce Car | Chief Scientific Officer | 0.04% |
| Julia Gregory | Independent Director | 0.02% |
| Kishan Mehta | Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Kimberly Gentile | Senior Vice President of Clinical Operations | Other Derivative Acquisition | +1,000 | $12.34 |
| 2026-08-05 | Infinitum Asset Management, LLC | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-07-08 | Warren Volles | General Counsel & Chief Legal Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-27 | John Childs | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Julia Gregory | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Robert Hugin | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Gregory Bailey | Independent Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Michael Heffernan | Lead Independent Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Irina Antonijevic | Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-04-27 | Kishan Mehta | Director | Other Derivative Acquisition | +68,693 | $9.61 |
| 2026-03-16 | Kishan Mehta | Director | Other Acquisition | +17,342 | -- |
| 2026-03-16 | Kishan Mehta | Director | Other Disposition | -17,342 | -- |
| 2026-02-26 | Matthew Buten | Chief Financial Officer | Other Derivative Acquisition | +175,000 | $11.52 |
| 2026-02-26 | Vladimir Coric | Chairperson & CEO | Other Derivative Acquisition | +550,000 | $11.52 |
| 2026-02-26 | Kimberly Gentile | Senior Vice President of Clinical Operations | Other Derivative Acquisition | +175,000 | $11.52 |
| 2026-02-26 | Bruce Car | Chief Scientific Officer | Other Derivative Acquisition | +175,000 | $11.52 |
| 2026-02-26 | George Clark | Vice President | Other Derivative Acquisition | +50,000 | $11.52 |
| 2026-01-04 | Matthew Buten | Chief Financial Officer | Derivative Exercise and Sale | -2,594 | $9.93 |
| 2026-01-04 | Matthew Buten | Chief Financial Officer | Derivative Exercise and Retained | +1,656 | -- |
| 2026-01-04 | Vladimir Coric | Chairperson & CEO | Derivative Exercise and Sale | -7,430 | $9.93 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 06:47:26 · For reference only, not investment advice and not tailored to your situation.